Tweet
Vaccine
. 2025 Jan 30:49:126780.
doi: 10.1016/j.vaccine.2025.126780. Online ahead of print. A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
Masayuki Hashimoto 1 , Kenichiro Tsujii 2 , Hitomi Nakajima-Yoshida 3 , Nobuteru Akiyama 4 , Ken Yoshihara 5 , Keiji Dohi 6 , Ziwei Yin 7 , Aki Ejima 8 , Saki Yamamoto-Mizuno 9 , Yasushi Nojiri 10 , Shou Saiki 11 , Kaoru Baba 12 , Shinya Omoto 13
Affiliations
Robust and broad protective immunity is typically elicited by co-administration of an adjuvant with vaccine antigens. A-910823, a squalene-based emulsion adjuvant, has been approved in Japan. It effectively enhances the humoral and cellular immunity of S-268019-b, a recombinant COVID-19 vaccine; however, the adjuvant effects of A-910823 on other vaccines, including influenza vaccine, have not been evaluated. Here, a ferret model was employed to investigate the adjuvant effects of A-910823 when combined with split-inactivated quadrivalent influenza vaccine (QIV). We demonstrate that combination of A-910823 with QIV enhances the neutralizing antibody titer and its breadth against non-vaccine strains. Also, the protective efficacy of A-910823-adjuvanted QIV against virus challenge has been confirmed. Of note, QIV combined with A-910823 caused only minor detectable side effects, whereas a significant increase in fever was observed after two doses of mRNA-LNP in ferrets. This study provides information on the effectiveness and safety of A-910823-adjuvanted QIV and suggests the usefulness of the ferret model for evaluating vaccine-induced reactogenicity.
Keywords: A-910823; Ferrets; Quadrivalent influenza vaccine; S-268019-b.
. 2025 Jan 30:49:126780.
doi: 10.1016/j.vaccine.2025.126780. Online ahead of print. A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets
Masayuki Hashimoto 1 , Kenichiro Tsujii 2 , Hitomi Nakajima-Yoshida 3 , Nobuteru Akiyama 4 , Ken Yoshihara 5 , Keiji Dohi 6 , Ziwei Yin 7 , Aki Ejima 8 , Saki Yamamoto-Mizuno 9 , Yasushi Nojiri 10 , Shou Saiki 11 , Kaoru Baba 12 , Shinya Omoto 13
Affiliations
- PMID: 39889536
- DOI: 10.1016/j.vaccine.2025.126780
Robust and broad protective immunity is typically elicited by co-administration of an adjuvant with vaccine antigens. A-910823, a squalene-based emulsion adjuvant, has been approved in Japan. It effectively enhances the humoral and cellular immunity of S-268019-b, a recombinant COVID-19 vaccine; however, the adjuvant effects of A-910823 on other vaccines, including influenza vaccine, have not been evaluated. Here, a ferret model was employed to investigate the adjuvant effects of A-910823 when combined with split-inactivated quadrivalent influenza vaccine (QIV). We demonstrate that combination of A-910823 with QIV enhances the neutralizing antibody titer and its breadth against non-vaccine strains. Also, the protective efficacy of A-910823-adjuvanted QIV against virus challenge has been confirmed. Of note, QIV combined with A-910823 caused only minor detectable side effects, whereas a significant increase in fever was observed after two doses of mRNA-LNP in ferrets. This study provides information on the effectiveness and safety of A-910823-adjuvanted QIV and suggests the usefulness of the ferret model for evaluating vaccine-induced reactogenicity.
Keywords: A-910823; Ferrets; Quadrivalent influenza vaccine; S-268019-b.